2seventy bio (TSVT) Divests R&D Assets to Regeneron, Stock Up
https://www.zacks.com/stock/news/2218877/2seventy-bio-tsvt-divests-r-d-assets-to-regeneron-stock-up?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2218877
Jan 31, 2024 - 2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.
0
EXEL or REGN: Which Is the Better Value Stock Right Now?
https://www.zacks.com/stock/news/2223576/exel-or-regn-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2223576
Feb 08, 2024 - EXEL vs. REGN: Which Stock Is the Better Value Option?
0
2 Top Growth Stocks to Buy With $1,000 Right Now
https://www.fool.com/investing/2024/02/18/2-top-growth-stocks-to-buy-with-1000-right-now/?source=iedfolrf0000001
Feb 17, 2024 - Even a modest starting investment in the right stocks could pay off in the years ahead.
0
Roche's (RHHBY) Xolair Gets Approval for Food Allergies
https://www.zacks.com/stock/news/2228151/roche-s-rhhby-xolair-gets-approval-for-food-allergies?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2228151
Feb 19, 2024 - Roche (RHHBY) obtains FDA approval for Xolair for the treatment of children and adults with one or more food allergies.
0
Bayer (BAYRY) Q4 Earnings Top, Crop Science Unit Drives Revenues
https://www.zacks.com/stock/news/2236717/bayer-bayry-q4-earnings-top-crop-science-unit-drives-revenues?cid=CS-ZC-FT-analyst_blog|earnings_article-2236717
Mar 06, 2024 - Bayer (BAYRY) beats earnings estimates in the fourth quarter of 2023, primarily driven by increased sales of Crop Science and Pharmaceuticals products.
0
Regeneron (REGN) Gets FDA Nod for Praluent Label Extension
https://www.zacks.com/stock/news/2239502/regeneron-regn-gets-fda-nod-for-praluent-label-extension?cid=CS-ZC-FT-analyst_blog|earnings_article-2239502
Mar 12, 2024 - Regeneron (REGN) obtains FDA approval for Praluent as an adjunct to diet and other LDL-C, lowering therapies to include pediatric patients aged eight and older with HeFH.
0
Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study
https://www.zacks.com/stock/news/2243015/intellia-ntla-begins-dosing-in-phase-iii-attr-amyloidosis-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243015
Mar 19, 2024 - Intellia (NTLA) doses the first patient in the phase III MAGNITUDE study on NTLA-2001 for treating transthyretin amyloidosis with cardiomyopathy.
0
EXEL or REGN: Which Is the Better Value Stock Right Now?
https://www.zacks.com/stock/news/2252785/exel-or-regn-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2252785
Apr 09, 2024 - EXEL vs. REGN: Which Stock Is the Better Value Option?
0
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why
https://www.zacks.com/stock/news/2257012/2seventy-bio-tsvt-rises-more-than-50-in-3-months-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2257012
Apr 17, 2024 - The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.
0
Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Should You Buy?
https://www.zacks.com/stock/news/2217967/deciphera-pharmaceuticals-inc-dcph-expected-to-beat-earnings-estimates-should-you-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2217967
Jan 30, 2024 - Deciphera Pharmaceuticals, Inc. (DCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Page 1>